LifeSciences BC > News > Member Announcements > Page 2

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

November 5, 2019
InMed Pharmaceuticals Inc.

Vancouver, BC – November 5, 2019 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms … Continue reading InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019

November 5, 2019
InMed Pharmaceuticals Inc.

Vancouver, BC – November 4, 2019 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended September … Continue reading InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019

Innovative Targeting Solutions and Former Amgen Executive Team up to Launch A2 Biotherapeutics with a $57 Million Series A

November 5, 2019
Innovative Targeting Solutions Inc.

Vancouver BC – November 5th, 2019 – Innovative Targeting Solutions (ITS) today announced that, A2 Biotherapeutics, Inc., co-founded in 2018 with Alexander Kamb, former SVP of Research at Amgen Inc., has emerged after operating in stealth mode for the last 18 months. With resources from a $57 million Series A financing, A2 Biotherapeutics is addressing the … Continue reading Innovative Targeting Solutions and Former Amgen Executive Team up to Launch A2 Biotherapeutics with a $57 Million Series A

DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083

November 5, 2019
DelMar Pharmaceuticals Inc.

SAN DIEGO, Nov. 5, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced it will host a cocktail reception featuring a panel discussion of Delmar’s glioblastoma multiforme (GBM) trial status with highly recognized thought leaders in GBM during the 2019 Society … Continue reading DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083

DR. MICHAEL HAYDEN JOINS ABCELLERA’S BOARD OF DIRECTORS

October 31, 2019
AbCellera Biologics Inc.

October, 31, 2019, Vancouver, B.C., – AbCellera, a leader in therapeutic antibody discovery from natural immune systems, has appointed Dr. Michael Hayden to its Board of Directors. Dr. Hayden replaces former Director Andrew Booth, who recently transitioned to an executive role as AbCellera’s Chief Financial Officer. “We are immensely pleased to have Dr. Hayden joining AbCellera’s Board … Continue reading DR. MICHAEL HAYDEN JOINS ABCELLERA’S BOARD OF DIRECTORS

Arbutus to Report Third Quarter 2019 Financial Results

October 30, 2019
Arbutus Biopharma Corp.

WARMINSTER, Pa., Oct. 30, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for Wednesday, November 6, 2019.  The schedule for the press release and conference call/webcast are as follows: • Q3 2019 Press Release: November 6, … Continue reading Arbutus to Report Third Quarter 2019 Financial Results

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update

October 29, 2019
XENON PHARMACEUTICALS INC.

BURNABY, British Columbia, Oct. 29, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2019 financial and operating results after the close of U.S. financial markets on Tuesday, November 5, 2019.  Xenon management will host a conference call and live audio webcast at … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update

DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual Meeting

October 29, 2019
DelMar Pharmaceuticals Inc.

SAN DIEGO, Oct. 29, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced that two posters updating results from the company’s two Phase 2 clinical trials of VAL-083 will be presented at the 2019 Society for NeuroOncology Annual meeting in Phoenix, … Continue reading DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual Meeting

DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

October 24, 2019
DelMar Pharmaceuticals Inc.

  SAN DIEGO, Oct. 24, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced that Mr. Saiid Zarrabian, president and chief executive officer of DelMar, will be a featured presenter at the 5th Annual Dawson James Small Cap Growth Conference on October … Continue reading DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

LifeSciences BC announces new appointments to Board of Directors

October 11, 2019
LifeSciences BC

October 3, 2019, Vancouver, BC – On behalf of LifeSciences BC, Wendy Hurlburt, President and CEO, is pleased to announce the appointment of new members to the LifeSciences BC Board of Directors. At the recent Board of Directors meeting, Scott Phillips was elected new Chair, Board of Directors with Nancy Harrison moving to Past Chair. … Continue reading LifeSciences BC announces new appointments to Board of Directors